Michael Savona, MD, professor of medicine and cancer biology, Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine, discusses phase 3 trial ASCERTAIN for the treatment of myelodysplastic syndrome (MDS) and chronic myelomonocytic leukemia (CMML). ASCERTAIN involves a combination of oral decitabine and cedazuridine compared to intravenous administration of decitabine alone. To date, the median follow up is two years, and the study still has not met median overall survival, so Dr. Savona is excited about the future of the study.
